AbGn-168H

Ligand id: 10013

Name: AbGn-168H

No information available.
Summary of Clinical Use
AbGn-168H has completed Phase 2 clinical evaluation in patients with moderate to severe chronic plaque psoriasis (NCT01855880) and active psoriatic arthritis (NCT02267642). A Phase 2 study in patients with moderate to severe active, anti-TNFα and/or anti-integrin refractory ulcerative colitis has been initiated (NCT03298022), as has a Phase 1 study for steroid-refractory acute graft-versus-host disease (GvHD; NCT03327857). FDA orphan drug designation for the treatment of acute GvHD was granted in January 2018 [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01855880 Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients Phase 2 Interventional AbGenomics B.V Taiwan Branch
NCT02267642 A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis Phase 2 Interventional AbGenomics B.V Taiwan Branch
NCT03298022 Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis Phase 2 Interventional AbGenomics International, Inc.
NCT03327857 Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease Phase 1 Interventional AbGenomics International, Inc.